The Virtue of Patients
Researching neurodegenerative diseases often feels like an unwinnable battle against biology. Despite decades of effort, we still have no means for reversing the effects of… Read More »The Virtue of Patients
drug development
Foghorn Therapeutics Breaks New Ground in Cancer Epigenetics
Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the… Read More »Foghorn Therapeutics Breaks New Ground in Cancer Epigenetics